Mitre Medical Corp CEO John MacMahon tells Proactive the privately-held group is developing a less invasive and safer approach to treat functional mitral valve regurgitation (MR) in patients with moderate to severe MR.
MacMahon says the group recently announced one-year results of the group's Mitral Touch in European patients, and looks forward to bringing the technology to the US within four different clinical sites.